Understanding Health-Related Quality of Life in Patients with Mantle Cell Lymphoma

Priyanka A. Pophali; Gita Thanarajasingam

doi:10.1016/j.hoc.2020.06.011

Understanding Health-Related Quality of Life in Patients with Mantle Cell Lymphoma

Priyanka A. Pophali, Gita Thanarajasingam

Hematology

Research output: Contribution to journal › Review article › peer-review

Abstract

Mantle cell lymphoma (MCL) is a unique lymphoma that is heterogeneous in its clinical course, and lacks consensus treatment approaches. It is often treated with immunochemotherapy at diagnosis and chronic therapies in relapse. Despite significant advances in therapy, MCL remains incurable. Maintaining patients’ health-related quality of life (HRQOL) is an important treatment goal. Assessment of HRQOL elucidates the impact of an illness and its treatment on patients’ lives. This review highlights the relevance of HRQOL assessment in MCL, evaluates existing evidence, current knowledge gaps and challenges in HRQOL assessment, and defines future directions for improving HRQOL evaluation in MCL patients.

Original language	English (US)
Pages (from-to)	971-982
Number of pages	12
Journal	Hematology/Oncology Clinics of North America
Volume	34
Issue number	5
DOIs	https://doi.org/10.1016/j.hoc.2020.06.011
State	Published - Oct 2020

Keywords

Adverse events
Chronic therapy
HRQOL
Mantle cell lymphoma
Patient-reported outcomes
Toxicity

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.hoc.2020.06.011

Cite this

@article{8163d0e487df45038b27f5713f6f4b59,

title = "Understanding Health-Related Quality of Life in Patients with Mantle Cell Lymphoma",

abstract = "Mantle cell lymphoma (MCL) is a unique lymphoma that is heterogeneous in its clinical course, and lacks consensus treatment approaches. It is often treated with immunochemotherapy at diagnosis and chronic therapies in relapse. Despite significant advances in therapy, MCL remains incurable. Maintaining patients{\textquoteright} health-related quality of life (HRQOL) is an important treatment goal. Assessment of HRQOL elucidates the impact of an illness and its treatment on patients{\textquoteright} lives. This review highlights the relevance of HRQOL assessment in MCL, evaluates existing evidence, current knowledge gaps and challenges in HRQOL assessment, and defines future directions for improving HRQOL evaluation in MCL patients.",

keywords = "Adverse events, Chronic therapy, HRQOL, Mantle cell lymphoma, Patient-reported outcomes, Toxicity",

author = "Pophali, {Priyanka A.} and Gita Thanarajasingam",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = oct,

doi = "10.1016/j.hoc.2020.06.011",

language = "English (US)",

volume = "34",

pages = "971--982",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders Ltd",

number = "5",

}

TY - JOUR

T1 - Understanding Health-Related Quality of Life in Patients with Mantle Cell Lymphoma

AU - Pophali, Priyanka A.

AU - Thanarajasingam, Gita

PY - 2020/10

Y1 - 2020/10

N2 - Mantle cell lymphoma (MCL) is a unique lymphoma that is heterogeneous in its clinical course, and lacks consensus treatment approaches. It is often treated with immunochemotherapy at diagnosis and chronic therapies in relapse. Despite significant advances in therapy, MCL remains incurable. Maintaining patients’ health-related quality of life (HRQOL) is an important treatment goal. Assessment of HRQOL elucidates the impact of an illness and its treatment on patients’ lives. This review highlights the relevance of HRQOL assessment in MCL, evaluates existing evidence, current knowledge gaps and challenges in HRQOL assessment, and defines future directions for improving HRQOL evaluation in MCL patients.

AB - Mantle cell lymphoma (MCL) is a unique lymphoma that is heterogeneous in its clinical course, and lacks consensus treatment approaches. It is often treated with immunochemotherapy at diagnosis and chronic therapies in relapse. Despite significant advances in therapy, MCL remains incurable. Maintaining patients’ health-related quality of life (HRQOL) is an important treatment goal. Assessment of HRQOL elucidates the impact of an illness and its treatment on patients’ lives. This review highlights the relevance of HRQOL assessment in MCL, evaluates existing evidence, current knowledge gaps and challenges in HRQOL assessment, and defines future directions for improving HRQOL evaluation in MCL patients.

KW - Adverse events

KW - Chronic therapy

KW - HRQOL

KW - Mantle cell lymphoma

KW - Patient-reported outcomes

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=85089108729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089108729&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2020.06.011

DO - 10.1016/j.hoc.2020.06.011

M3 - Review article

C2 - 32861290

AN - SCOPUS:85089108729

SN - 0889-8588

VL - 34

SP - 971

EP - 982

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

IS - 5

ER -

Understanding Health-Related Quality of Life in Patients with Mantle Cell Lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this